Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | CNOT7 | Q9UIV1 | 10/20 | 0.43 |
| ▸ | PARN | O95453 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9386885 | 0.99 | ALDH1A1 (0.59) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL9300704 | 0.89 | LMNA (0.57) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL9387987 | 0.85 | CNOT7 (0.45) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL13217674 | 0.83 | ALDH1A1 (0.66) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL4534193 | 0.81 | LMNA (0.62) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL9387776 | 0.80 | CNOT7 (0.43) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL13659011 | 0.79 | ALDH1A1 (0.60) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL9299928 | 0.79 | LMNA (0.60) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL4532803 | 0.79 | ALDH1A1 (0.60) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL9386947 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1LMNAMAPTTSHRCNOT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1082546-A | 7-neo-pentyl xanthine derivative, their preparation and include their pharmaceutical composition | MALESCI SAS (IT) | 1994-02-23 | — | — | CN | claimed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| CN-1082546-A | 7-neo-pentyl xanthine derivative, their preparation and include their pharmaceutical composition | MALESCI SAS (IT) | 1994-02-23 | — | — | CN | disclosed |
| WO-1994000452-A1 | 7-NEOPENTYL XANTHINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | ALDH1A1 1368/4885LMNA 2043/4885CYP3A4 4247/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | ALDH1A1 1378/4885LMNA 2244/4885CYP3A4 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.